National Accountability Bureau (NAB) has sought records from a leading private laboratory pertaining to the procurement of the COVID-19 vaccine from Russia and its proposed plan to earn over $100 per person in profit.
According to details, NAB Lahore initiated the investigation after a complaint was filed in the regional headquarter which contended that a renowned private laboratory has planned to charge $125 per person for Russia’s Coronavirus vaccine, Sputnik V.
A senior NAB official has said that the Russian Direct Investment Fund (RDIF), which invested in Moscow’s Gamaleya Institute for the development of the Coronavirus vaccine, has confirmed that it would sell each dose of Sputnik V for $10 which means that the two-dose vaccine would cost $20.
On the other hand, the laboratory in question has planned to sell the two-dose Sputnik V for $125 or approximately Rs. 20,000 in the local market, the official said.
The official added that sections 33C and 27 of the NAB Ordinance 1999 authorize NAB to check excessive profiteering causing the public to lose its money.
Note that earlier this month, the federal government had decided to allow medical companies and laboratories to set the prices of the Coronavirus vaccines without any interference from the government.